Serum vascular endothelial growth factor; an activation marker and prognostic indicator in sarcoidosis? Source: Eur Respir J 2005; 26: Suppl. 49, 80s Year: 2005
Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker? Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008
A soluble adhesion molecule ‘E-selectin‘; an activation marker and prognostic indicator in sarcoidosis? Source: Eur Respir J 2005; 26: Suppl. 49, 685s Year: 2005
Clinical value of soluble interleukine-2 receptor (sIL-2R) serum level examination in the pulmonary sarcoidosis (PS) Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis? Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019
The role of CRP as the activity marker during the course of sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 115s Year: 2007
Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105) Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009
Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019
Is YKL-40 a prognostic marker in sarcoidosis? Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Serum kinetics of total leptin and soluble leptin receptor as prognostic tools in sepsis. Source: International Congress 2019 – Biomarkers, laboratory findings and pre-clinical data in acute respiratory failure Year: 2019
YKL-40, soluble IL-2 receptor, ADA and neopterin: comparison of markers of sarcoidosis activity Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009
Plasma level of total hydroperoxide (TH) as a marker of oxidative stress seems to be a useful index of disease severity in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005
Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017
Circulating fibrocytes and collagen turnover products in UIP: marker of disease activity and prognostic tool? Source: Eur Respir J 2007; 30: Suppl. 51, 118s Year: 2007
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017
TNF-a and IL-10 control macrophage expression of CXCL13, a prognostic biomarker of idiopathic pulmonary fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018